Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of intravitreal pegaptanib sodium in diabetic macular edema
2010-020946-80Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegaptanib sodium in diabetic macular edema (DME), diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM), sponsored by Pfizer. Primary endpoint: Primary safety and tolerability endpoint. Started Aug 2010; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
diabetic macular edema (DME)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-020946-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020946-80.